Sign in Sign up for free

Last updated: 13 November 2023 at 4:51pm EST

Thomas J. Farley CPA Net Worth




The estimated Net Worth of Thomas J Farley is at least $1.23 Thousand dollars as of 26 May 2021. Mr Farley owns over 2,500 units of ADiTx Therapeutics stock worth over $1,225 and over the last 3 years he sold ADTX stock worth over $0.

Mr CPA ADTX stock SEC Form 4 insiders trading

Mr has made over 1 trades of the ADiTx Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of ADTX stock worth $6,700 on 26 May 2021.

The largest trade he's ever made was buying 2,500 units of ADiTx Therapeutics stock on 26 May 2021 worth over $6,700. On average, Mr trades about 833 units every 0 days since 2021. As of 26 May 2021 he still owns at least 2,500 units of ADiTx Therapeutics stock.

You can see the complete history of Mr Farley stock trades at the bottom of the page.





Mr. Thomas J. Farley CPA biography

Thomas J. Farley CPA is the Chief Financial Officer at ADiTx Therapeutics.



How old is Mr CPA?

Mr CPA is 47, he's been the Chief Financial Officer of ADiTx Therapeutics since . There are 11 older and 1 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.

What's Mr CPA's mailing address?

Thomas's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.

Insiders trading at ADiTx Therapeutics

Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin, and Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.



What does ADiTx Therapeutics do?

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.



What does ADiTx Therapeutics's logo look like?

ADiTx Therapeutics, Inc. logo

Complete history of Mr Farley stock trades at ADiTx Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
26 May 2021 ADTX ADiTx Therapeutics, Inc. Thomas J Farley
Chief Financial Officer
 Buy 2,500 $2.68 $6,700
26 May 2021
2,500 ↗


ADiTx Therapeutics executives and stock owners

ADiTx Therapeutics executives and other stock owners filed with the SEC include: